SAFETY OF COMBINED INSULIN AND SULFONYLUREA THERAPY FOR TYPE II DIABETES

胰岛素和磺脲类联合疗法治疗 II 型糖尿病的安全性

• 批准号: 3850299
• 负责人: MATTHEW C RIDDLE
• 金额: --
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3850299
• 关键词: combination chemotherapy; diabetes mellitus therapy; exercise; fasting; glucose metabolism; glucose tolerance test; human subject; human therapy evaluation; hypoglycemia; insulin; noninsulin dependent diabetes mellitus; sulfonylurea

Clinical studies suggest combined insulin-sulfonylurea therapy may yield less glycemic variability than insulin alone. This CRC protocol studies this concept by comparing the two regimens with respect to 1) glycemic variability over 24 hours, and 2) tendency to hypoglycemia with fasting plus mild exercise. Ten subjects will be studied in a crossover design, with two 3-day stays in the CRC.

临床研究表明，联合胰岛素磺脲类药物治疗可能会产生 血糖变异性比单独使用胰岛素更小。 本CRC方案研究 通过比较两种方案的1）血糖 24小时内的变异性，和2）空腹时低血糖倾向 再加上温和的锻炼。 10名受试者将采用交叉设计进行研究， 在康复中心住了两天